Kymera Therapeutics, Inc. (KYMR)

Kymera Therapeutics Stock Forecast

Stock Price Forecast

According to 23 analysts polled by S&P Global, Kymera Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $123.76. The average 1-year stock price forecast is 6.38% higher than the current stock price, while the lowest is $97 (-16.62%) and the highest is $155 (+33.23%).

Price Target: $123.76 (+6.38%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$97	$123.76	$120	$155
Change	-16.62%	+6.38%	+3.15%	+33.23%

Analyst Ratings

The average analyst rating for Kymera Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	17	17	17	17	18	17
Buy	5	5	5	5	5	5
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	23	23	23	23	24	23

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Daniel Giraldo Bank of America Securities	Bank of America Securities	Buy Reiterates $110 → $125	Buy	Reiterates	$110 → $125	+7.44%	Jun 30, 2026
Srikripa Devarakonda Truist Financial	Truist Financial	Buy Reiterates $116 → $136	Buy	Reiterates	$116 → $136	+16.90%	Jun 29, 2026
Mayank Mamtani B. Riley Securities	B. Riley Securities	Buy Reiterates $117 → $155	Buy	Reiterates	$117 → $155	+33.23%	Jun 29, 2026
Edward Nash Canaccord Genuity	Canaccord Genuity	Buy Reiterates $106 → $129	Buy	Reiterates	$106 → $129	+10.88%	Jun 26, 2026
Unknown Analyst Wells Fargo No rating	Wells Fargo	Buy Reiterates $116	Buy	Reiterates	$116	-0.29%	Jun 26, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

84.46M

Increased by 115.40%

from 39.21M

Revenue Next Year

41.02M

Decreased by -51.44%

from 84.46M

EPS This Year

-3.52

from -3.69

EPS Next Year

-4.35

from -3.52

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	72.83M	46.83M	78.59M	47.07M	39.21M	84.46M
Revenue Growth	114.00%	-35.71%	67.84%	-40.11%	-16.70%	115.40%
Operating Income	-100.53M	-161.26M	-165.53M	-256.71M	-345.54M	-390.38M
Net Income	-100.22M	-154.81M	-146.96M	-223.86M	-311.35M	-341.15M
EPS	-	-	-	-	-3.69	-3.52
Free Cash Flow	-58.30M	-90.21M	-97.62M	-126.83M	-136.04M	-317.91M
No. Analysts	-	-	-	-	-	21

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	124.0M
Avg	84.5M
Low	41.7M

Revenue Growth

Revenue Growth	2026	2027	2028
High	216.2%
Avg	115.4%
Low	6.3%

EPS Forecast

EPS	2026	2027	2028
High	-2.64
Avg	-3.52
Low	-5.51

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-

Data Sources: S&P Global Market Intelligence and TipRanks Last updated: Jun 30, 2026

Price targets, consensus ratings and financial forecasts are provided by S&P Global Market Intelligence. Individual analyst data is provided by TipRanks. Price targets and consensus ratings update every hour to every three days, while individual analyst data updates in near real-time.

Last checked:

Jun 30, 2026

Data Sources Report a data error